Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense
This article was originally published in The Pink Sheet Daily
Executive Summary
Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.